Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera

A retrospective, cross-sectional analysis demonstrated that 16.3% patients with polycythemia vera (PV) receiving hydroxyurea experienced thromboembolic events within the first year of starting treatment, which leads to increased inpatient admissions and emergency room visits and significantly higher annual healthcare costs for patients.

 Journal of Managed Care & Specialty Pharmacy

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.